Publications by authors named "Ellis Adamson"
Article Synopsis
- Relugolix is an oral medication used in the UK for advanced hormone-sensitive prostate cancer, often combined with treatments like radiotherapy and enzalutamide.
- A case study of a 66-year-old man with prostate cancer showed that after switching from leuprorelin to relugolix while continuing enzalutamide, his PSA levels significantly dropped and remained stable for 11 months.
- The combination of relugolix and enzalutamide was well tolerated, suggesting potential for further research into their use together in treating prostate cancer.
We present a case of prostate-specific antigen (PSA) bounce in a 76 year old man who underwent salvage radiotherapy to the prostate bed following biochemical relapse 6 years post-radical prostatectomy for a T2N0 Gleason grade 3 + 3 prostate adenocarcinoma; 10 months following completion of salvage radiotherapy for biochemical PSA recurrence of 0.2 μg/L. Following undetectable results (<0.
View Article and Find Full Text PDF